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OBJECTIVES The goal of this study was to compare the impact of primary stenting or percutaneous
transluminal coronary angioplasty (PTCA) on health-related quality of life (HRQOL) in
patients undergoing direct angioplasty for acute myocardial infarction (AMI).
BACKGROUND Previous studies have demonstrated that coronary stenting reduces clinical and angiographic
restenosis compared with PTCA. However, the impact of stenting on HRQOL from the
patient’s perspective remains unknown.
METHODS We administered the Seattle Angina Questionnaire and the Medical Outcomes Study
Short-form Survey at 1, 6 and 12 months after initial treatment to all North American
patients in the Stent-Primary Angioplasty for Myocardial Infarction trial (Stent-PAMI) (n
509)—a randomized trial comparing primary stenting to conventional PTCA for patients
with AMI.
RESULTS At one month, most HRQOL measures were similar for the two groups, but stent patients
reported less bodily pain than PTCA patients (p  0.03). At six-month follow-up, stenting
resulted in significant improvements in several dimensions of HRQOL including reduced
anginal frequency and bodily pain as well as improved disease perception (all p  0.03) and
a trend towards better anginal stability (p  0.056). By 12-month follow-up, however, none
of these differences remained statistically significant. These differences in HRQOL were
largely explained by the greater need for ischemia-driven target-vessel repeat revascularization
procedures in PTCA patients during the first six months (16.0% vs. 6.2%, p  0.001).
CONCLUSIONS In patients undergoing revascularization for AMI, initial stent placement is associated with
improvements in several dimensions of health status during the first six months of follow-up.
In the absence of differences in mortality, these findings add to the overall argument in
favor of initial stenting in patients treated with mechanical reperfusion for myocardial
infarction. (J Am Coll Cardiol 2001;38:1614–21) © 2001 by the American College of
Cardiology
Over the past decade, coronary stenting has been shown to
reduce the rates of angiographic and clinical restenosis
compared with conventional balloon angioplasty. Although
these benefits were initially established in the setting of
elective percutaneous coronary intervention (PCI) (1–3),
recent studies have shown that these benefits extend to
patients undergoing direct PCI for acute myocardial infarc-
tion (AMI) as well (4–6). As a result, stenting has emerged
as the dominant form of percutaneous coronary revascular-
ization. Currently, more than 70% of all PCIs performed in
the U.S. involve placement of one or more coronary stents
(7).
Despite their prominent position in the current practice
of interventional cardiology, certain unresolved questions
remain about the true value of coronary stenting (8).
Although stents have been clearly demonstrated to reduce
follow-up medical care costs compared with balloon angio-
plasty alone, overall medical care costs remain higher in
most studies (9–11). Moreover, no randomized studies to
date have demonstrated that coronary stenting improves
short or long-term survival compared with conventional
percutaneous transluminal coronary angioplasty (PTCA)
(10–12). Thus, the ultimate value of coronary stenting is
highly dependent on its impact on overall health-related
quality of life (HRQOL).
Although several studies have examined HRQOL after
stenting or balloon angioplasty, these studies are limited by
their retrospective nature (13) or extremely high rates of
treatment crossover (14). In addition, no studies have
specifically examined the impact of stenting on quality of
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life (QOL) after AMI. To address these unresolved issues,
we performed a prospective HRQOL substudy in the
Stent-Primary Angioplasty for Myocardial Infarction trial
(Stent-PAMI).
METHODS
Study population. Between December 1996 and Novem-
ber 1997, 900 patients with AMI were randomized to
routine coronary stent placement or primary PTCA as part
of the Stent-PAMI trial. Details of the study protocol have
been described previously (5). Briefly, patients presenting
with AMI within 12 h of the onset of symptoms were
referred for emergent coronary angiography. If angiography
confirmed the presence of a high-grade native coronary
stenosis suitable for either balloon angioplasty or stent
implantation, the patient was eligible for randomization.
The study protocol was approved by the institutional review
board at each site, and all patients provided informed
consent before enrollment.
Randomization and treatment protocol. Eligible patients
were randomized to treatment with either conventional
PTCA or the heparin-coated, Palmaz-Schatz stent (Cordis,
Johnson and Johnson, Warren, New Jersey). Balloon angio-
plasty and stenting were performed according to standard
techniques, including high-pressure postdilation after stent
placement. Crossover from PTCA to stent placement was
discouraged unless required to treat a severe dissection or an
unacceptable PTCA result (50% residual stenosis). After
stent placement, patients received ticlopidine (250 mg twice
a day) for one month. The remainder of each patient’s care
was left to the discretion of the primary treating physician.
Assessment of in-hospital outcomes and clinical follow-
up. Detailed case report forms including baseline demo-
graphics, clinical data and events during the initial hospi-
talization and follow-up were completed at each site and
forwarded to the data-coordinating center (Cardialysis,
Rotterdam, the Netherlands). All patients underwent clin-
ical follow-up at 1, 6 and 12 months after initial treatment.
Ischemia-driven target-vessel revascularization (TVR) was
defined as any repeat revascularization of the original treated
vessel that was required because of recurrent angina (Cana-
dian Cardiovascular Society [CCS] class 2 to 4) or ischemia
on functional testing. All end points including ischemia-
driven TVR were adjudicated by an independent clinical
events committee who were blinded to treatment assign-
ment.
HRQOL. Health-related QOL was assessed at 1, 6 and 12
months after randomization using the Medical Outcomes
Study (MOS) Short-form Survey (SF-36) and the Seattle
Angina Questionnaire (SAQ) (15–18). Baseline health
status was not assessed during the index hospitalization
because of concerns about reliability of these instruments in
the immediate post-myocardial infarction (MI) setting. The
SF-36 is a generic health status instrument that evaluates
eight dimensions of health including physical function,
social function, mental health, general health perception,
pain, energy and fatigue and two types of role function
(15,16). The SAQ is a disease-specific instrument that
measures five dimensions of QOL that are particularly
important to patients with coronary artery disease (CAD):
physical limitations due to CAD, anginal stability, anginal
frequency, treatment satisfaction and disease perception
(17,18). All SF-36 and SAQ domains are scaled from 0 to
100 points, with higher scores indicating better QOL (e.g.,
less pain, less frequent angina, better disease perception,
etc.). Both instruments have undergone extensive validity
and reliability testing and are sensitive to clinically mean-
ingful differences in QOL (19). In our study population, the
SF-36 demonstrated excellent internal consistency accord-
ing to Cronbach’s , with values ranging between 0.80 and
0.94 for all domains at 1, 6 and 12 months. Internal
consistency for the SAQ was somewhat lower but still
acceptable, with Cronbach’s  0.62 for each subscale at
each time point (20). Because the SAQ was validated only
in its English version at the time of study initiation, only
patients enrolled at U.S. and Canadian hospitals were
eligible for the HRQOL substudy.
At each follow-up time point, patients were provided
with a self-administered survey booklet and stamped return
envelope. Any patient who failed to return the survey by the
time of phone contact was given the survey by telephone (or
in person at the time of the clinic visit).
Statistical analysis. Discrete data are reported as frequen-
cies and continuous data as mean  SD. Baseline charac-
teristics and outcome variables were compared between
treatment groups with the use of the two-sample t test for
continuous variables and Fisher exact test for categorical
variables. Nonnormally distributed continuous data were
compared using the Wilcoxon rank-sum test.
We used two-way analysis of variance to assess the extent
to which HRQOL scores improved over time within the
two treatment groups. Two-sample t tests were performed
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to compare HRQOL scores between treatment arms at each
time point. Since each HRQOL domain was evaluated at
three time points, we used the method of Benjamini and
Hochberg (21) to adjust for multiple comparisons. Al-
though our primary analyses were based on all of the
available HRQOL data, extensive sensitivity analyses were
performed using various imputation strategies to assess the
impact of missing data on our findings. Since there were
minor imbalances in several covariates at baseline, we also
used multiple linear regression analyses to evaluate the
treatment effect at six months while adjusting for baseline
differences. All analyses were based on the intention-to-
treat principle. All p values are two-tailed, and a p value
0.05 was considered statistically significant. All statistical
analyses were performed with SAS statistical software,
versions 6.12 and 8 (SAS Institute, Cary, North Carolina).
RESULTS
Of the 900 patients randomized in the Stent-PAMI trial,
554 were enrolled in North American centers and were
eligible for the HRQOL substudy. Of these, 509 (92%)
completed at least one QOL questionnaire and formed the
population for the substudy. In general, responders and
nonresponders were similar. However, questionnaire non-
responders were more likely to have a history of transient
ischemic attack (11.1% vs. 4.0%, p  0.01) or stroke (10.8
vs. 3.4%, p 0.05) and had lower baseline ejection fractions
(44% vs. 47%, p  0.05). There were no differences in
treatment allocation between responders and nonre-
sponders.
Baseline characteristics. Among the 509 responders, base-
line characteristics were generally comparable between the
two treatment groups (Table 1). Patients assigned to coro-
nary stenting tended to be somewhat older than patients in
the PTCA group (60.7 vs. 58.8 years, p  0.07), had a
slightly higher prevalence of hypercholesterolemia (46.4%
vs. 37.8%, p  0.08) and stroke (4.7% vs. 2.0%, p  0.09)
and a lower prevalence of chronic obstructive pulmonary
disease (COPD) (2.0% vs. 5.5%, p  0.06).
Clinical outcomes. Mortality rates in the HRQOL sub-
study were lower than those in the overall clinical trial since
patients who died within the first month of follow-up were
not eligible for QOL evaluation. Otherwise, clinical out-
comes in the HRQOL substudy closely paralleled the
outcomes seen in the overall randomized trial (Table 2).
Over the one-year follow-up period, there were no signifi-
cant differences between the treatment groups in the inci-
dence of death, nonfatal reinfarction or stroke. In contrast,
patients randomized to initial stenting were less likely than
those assigned to conventional PTCA to require repeat
TVR because of recurrent angina or ischemia over the
follow-up period (12.1% vs. 24.2%, p  0.001). Of these
repeat revascularization procedures, 64% were performed
during the first six months of follow-up while 36% were
performed during months 7 to 12.
HRQOL outcomes. Results of the QOL surveys at each
follow-up time point are displayed graphically in Figures 1
and 2. Health-related QOL scores improved over the
follow-up period for three of five domains of the SAQ
(anginal frequency, disease perception and physical limita-
tions due to heart disease; all p  0.001) and for seven of
eight domains of the SF-36 (all except general health
perception; all p  0.001). The only exception to this
pattern was the results for the SAQ anginal stability score,
which measures the extent of change in a patient’s disease
status over the preceding month (50  no change, 51 to
100  improvement, 0 to 49  decline). Thus, the high
scores for this scale at one month reflect dramatic improve-
ments in cardiovascular health relative to the time of
enrollment in the study. Although scores tended to decline
at months 6 and 12, they remained higher than 50 for both
treatment groups, which indicates continued improvement
Table 1. Baseline Characteristics
Stent
(n  254)
PTCA
(n  255) p Value
Age (yrs) 60.7  12.0 58.8  12.4 0.07
Male gender (%) 71 74 0.49
Previous MI (%) 10.2 11.5 0.67
Previous CABG (%) 2.0 1.6 1.0
Diabetes mellitus (%) 16.1 15.0 0.81
Hypercholesterolemia (%) 46.4 37.8 0.08
Current smoker (%) 39.1 45.4 0.27
Hypertension (%) 41.7 42.3 0.93
Previous stroke (%) 4.7 2.0 0.09
Peripheral vascular disease (%) 2.4 4.3 0.32
COPD (%) 2.0 5.5 0.06
Multivessel disease (%) 46.9 45.1 0.91
Ejection fraction (%) 47  12 47  11 0.95
CABG  coronary artery bypass surgery; COPD  chronic obstructive pulmonary
disease; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty.
Table 2. Clinical Outcomes in the HRQOL Substudy at 6 and
12 Months After Randomization
Stent
(n  254)
PTCA
(n  255) p Value
6 Months
Death (%) 0.4 0.4 1.0
MI (%) 4.1 3.7 1.0
Stroke (%) 1.2 0.4 0.62
Ischemia-driven TVR 6.1 16.0  0.001
PCI (%) 4.9 13.5 0.002
CABG (%) 1.2 2.9 0.34
12 Months
Death (%) 1.7 0.8 0.69
MI (%) 4.6 5.6 0.68
Stroke (%) 1.7 0.4 0.37
Ischemia-driven TVR 12.1 24.2  0.001
PCI (%) 8.2 19.5  0.001
CABG (%) 4.2 5.6 0.53
All events rates are cumulative incidence rates from randomization.
CABG  coronary artery bypass surgery; HRQOL  health-related quality of
life; MI myocardial infarction; PCI percutaneous coronary intervention; TVR
target-vessel revascularization.
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in anginal stability, but to a lesser degree, over the succeed-
ing months.
At the one-month time point, there were few differences
in HRQOL between the treatment groups. The only
exceptions were for the SF-36 bodily pain (mean differ-
ence  7.0, p  0.03) and mental health scales (mean
difference  4.4, p  0.056), both of which favored the
stent group. At the six-month time point, patients assigned
to initial stenting had higher scores for multiple dimensions
of HRQOL including reduced anginal frequency (mean
difference 5.7, p 0.02), better disease perception (mean
difference  6.8, p  0.03) and improved anginal stability
(mean difference  7.3, p  0.056) according to the SAQ,
as well as reduced bodily pain (mean difference  7.0, p 
0.03) according to the SF-36. By 12-month follow-up,
however, none of these differences remained statistically
significant.
In order to adjust for slight imbalances between the stent
and PTCA groups, we used multiple linear regression to
examine the relationship between HRQOL at six months
and treatment assignment. Of those factors that differed
between the stent and PTCA groups at baseline (p 0.10),
only the presence of COPD was associated with QOL
during follow-up. In multivariable analyses that controlled
for the presence of COPD, randomization to coronary
stenting remained independently associated with improved
six-month QOL across all of the domains identified in the
primary analyses.
Health-related QOL data were missing for 14% to 36%
of our study population (mean  22%) across the various
domains and time points. There were no differences in
the rates of missing data between the two treatment
groups. To examine the robustness of our results, we
performed a variety of sensitivity analyses in which we
Figure 1. Health-related quality of life 1, 6 and 12 months after stenting versus percutaneous transluminal coronary angioplasty (PTCA) for treatment of
acute myocardial infarction, as assessed by the Seattle Angina Questionnaire.
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imputed missing data using the worst health status score,
the best health status score, the mean value for the treat-
ment group and a last-value-carried-forward approach.
None of our principal findings were altered in any of these
sensitivity analyses.
Since the major benefit of stenting in our patient popu-
lation was a reduction in the need for clinically-driven TVR,
we performed stratified analyses to explore the relationship
between treatment assignment, TVR and HRQOL at the
six-month time point (Table 3). The occurrence of isch-
emia-driven TVR during follow-up was associated with
substantially worse HRQOL scores across virtually all
domains, with differences ranging from 4.2 points for the
SAQ treatment satisfaction subscale to 14.5 for the physical
role function subscale of the SF-36. Nonetheless, among
patients who did not require TVR during follow-up, stent-
ing was still associated with improved six month anginal
frequency, disease perception, anginal stability and bodily
pain scores. We observed similar findings in favor of
stenting in the subgroup of patients who did require TVR
Figure 2. Health-related quality of life 1, 6 and 12 months after stenting versus percutaneous transluminal coronary angioplasty (PTCA) for treatment of
acute myocardial infarction, as assessed with the MOS SF-36 Questionnaire.
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during follow-up as well. At one-year follow-up, freedom
from ischemia-driven revascularization was associated with
persistent HRQOL benefits across nearly all the SAQ and
SF-36 domains (data not shown).
DISCUSSION
Although coronary stenting reduces restenosis compared
with conventional PTCA, most studies have found that
aggregate long-term costs remain somewhat higher with
stenting regardless of the clinical setting (9–11,22). Thus, in
the current era of constrained resources, justification for
routine coronary stenting requires evidence of meaningful
long-term benefits as assessed from the patient’s perspective.
Since most studies of stenting have not demonstrated
reduced long-term mortality compared with PTCA alone
(10–12,23,24), the value of routine coronary stenting de-
pends critically on its ability to improve HRQOL compared
with alternative revascularization procedures.
In this study, we prospectively evaluated HRQOL in a
large population of North American patients who were
randomized to stenting or conventional PTCA as treatment
for AMI. Using two well-validated instruments (the SF-36
health status instrument and the SAQ), we found that
stenting produced substantial improvements in HRQOL
compared with PTCA alone. These benefits were princi-
pally manifest at the six-month follow-up time point and
were no longer apparent 12 months after initial treatment.
Nonetheless, patients who required one or more repeat
revascularization procedures during follow-up demonstrated
persistent reductions in QOL across both general and
cardiac-specific domains.
Comparison with previous studies. Two previous studies
have attempted to assess the HRQOL benefits of stenting
compared with PTCA for patients undergoing nonemer-
gent PCI (13,14). Krumholz et al. (13) used the SF-36,
Duke Activity Status Index and CCS anginal classification
to examine HRQOL in 160 patients who were randomly
assigned to stenting or PTCA as part of the Stent Resten-
osis study (13). At a median follow-up interval of 15
months, they found no major differences in HRQOL with
the exception of the SF-36 pain scale, which favored
stenting. However, this study was limited by its retrospec-
tive nature, modest sample size, lack of a disease-specific
instrument and the prolonged interval between initial treat-
ment and follow-up health assessment. More recently, the
Optimum PTCA compared with Routine Stent Strategy
(OPUS) trial used the SAQ to evaluate HRQOL six
months after randomization to routine stenting or a provi-
sional stenting strategy (14). In this prospective study of 431
patients, there were no differences in any of the SAQ
subscales despite a significant reduction in TVR with
stenting. Whether these differences between OPUS and our
study are due to inherent differences in the patient popula-
tions (planned PCI vs. AMI intervention), the high rate of
crossover from angioplasty to stent implantation in the
provisional stent arm of OPUS (37%) or our larger sample
size and greater statistical power is uncertain. Of note is
that, similar to our study, the OPUS trial demonstrated
substantial differences in six-month HRQOL between pa-
tients who did and did not require repeat revascularization
during follow-up.
Clinical significance. At the six-month time point, the
differences in HRQOL between stenting and PTCA ranged
from 5.7 points for the SAQ anginal frequency scale to 6.8
points and 7.0 points for the SAQ disease perception and
the SF-36 bodily pain scales, respectively. On a population
basis, such differences in health status are fairly large. For
example, a cross-sectional study of population-based means
Table 3. Six-Month HRQOL According to Treatment Assignment and the Need for Ischemia-Driven TVR During the
One-Year Follow-Up
No TVR (n  379) TVR (n  84)
No TVR-TVR
(95% CI)Stent PTCA
Stent-PTCA
(95% CI) Stent PTCA
Stent-PTCA
(95% CI)
SAQ Subscales
Anginal frequency 94.1 89.1 5.0 (1.7, 8.3) 85.4 79.8 5.6 (5.2, 16.5) 10.1 (5.9, 14.4)
Disease perception 78.5 73.2 5.3 (0.4, 10.2) 73.6 62.2 11.4 (1.5, 24.3) 10.0 (4.0, 15.9)
Anginal stability 83.5 75.9 7.6 (1.7, 13.6) 76.1 72.8 3.3 (12.3, 19.0) 6.2 (0.9, 13.3)
Physical limitation 85.4 85.1 0.3 (4.7, 5.2) 85.7 78.6 7.1 (4.7, 18.9) 4.4 (1.6, 10.3)
Treatment satisfaction 86.3 83.5 2.8 (0.2, 5.9) 82.9 79.9 3.0 (5.9, 11.9) 4.2 (0.4, 7.9)
SF-36 Subscales
Bodily pain 81.0 75.9 5.2 (0.0, 10.3) 78.1 67.6 10.5 (1.2, 22.1) 7.8 (1.6, 13.9)
General health 70.3 66.7 3.6 (0.7, 7.9) 66.0 59.6 6.3 (4.5, 17.1) 7.0 (1.8, 12.2)
Physical functioning 78.5 77.5 1.0 (4.3, 6.3) 78.9 71.7 7.1 (5.2, 19.5) 4.0 (2.4, 10.3)
Vitality 63.9 59.5 4.4 (0.9, 4.2) 59.1 53.9 5.2 (5.3, 15.7) 6.4 (0.7, 12.0)
Role-physical 75.3 74.2 1.1 (7.0, 9.1) 69.8 55.6 14.2 (7.3, 35.7) 14.5 (4.7, 24.4)
Role-emotional 82.8 82.6 0.2 (6.9, 7.3) 82.3 62.6 20.2 (0.2, 41.7) 13.3 (4.4, 22.2)
Social functioning 87.8 85.3 2.5 (2.4, 7.4) 77.6 77.3 0.3 (12.8, 13.4) 9.2 (3.3, 15.2)
Mental health 78.8 77.6 1.3 (2.7, 5.2) 76.3 68.3 8.0 (1.9, 18.0) 7.4 (2.6, 12.2)
CI  confidence interval; HRQOL  health-related quality of life; PTCA  percutaneous transluminal coronary angioplasty; SAQ  Seattle Angina Questionnaire; SF-36 
Medical Outcomes Study Short-form Survey; TVR  target-vessel revascularization.
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by age group revealed that decrements of 4 to 7 points in
SF-36 scores were associated with five years of aging (25).
Moreover, a previous longitudinal study of patients with
chronic stable angina found that differences in SAQ scores
of approximately 8 points were clinically meaningful for all
but the anginal stability subscale (18).
Examination of the individual items that comprise each
subscale can also improve the interpretability of the ob-
served differences in HRQOL. For example, in our study
the 7 point difference on the SF-36 bodily pain subscale
indicates that at six-month follow-up 25% of patients
assigned to initial PTCA reported “moderate, severe or very
severe pain during the last four weeks” as compared with
only 16% of patients assigned to initial stenting (p  0.03).
Similarly, 23% of patients who had received PTCA had
reported “moderate to extreme interference with normal
work due to pain” compared with only 13% of patients
receiving stents (p  0.01). For the SAQ anginal frequency
subscale, the observed 6 point difference at six-month
follow-up indicates that 43% of patients who had received
PTCA experienced one or more chest pain episodes during
the month preceding the questionnaire compared with 26%
of patients who had received stents (p  0.01), and 18% of
patients who had received PTCA reported that they have
used some nitroglycerin over the same period (vs. 10% of
patients receiving stents, p  0.03). On the basis of these
comparisons, it appears that the HRQOL benefits that were
associated with stenting in Stent-PAMI are clinically rele-
vant.
Mechanisms of benefit. The major clinical benefit of
stenting compared with PTCA in our study was a reduction
in the need for ischemia-driven TVR, which was apparent
by six-month follow-up and sustained through one year.
The major benefit of stenting on HRQOL was observed at
the six-month time point as well. The timing of these
benefits suggests that much of the HRQOL benefits of
stenting relate to its ability to reduce restenosis and its
associated complications. In this light, it is not surprising
that the QOL benefits associated with stenting were no
longer apparent at one-year follow-up. By this time point, it
is likely that most episodes of symptomatic restenosis had
already occurred and been successfully treated with repeat
revascularization.
Nonetheless, our stratified analyses suggest that restenosis
(or at least its clinical manifestation as repeat TVR) does not
fully account for the observed differences in HRQOL
between treatment groups. In fact, stenting was associated
with slightly better QOL scores regardless of whether
patients underwent ischemia-driven TVR or not (Table 3).
There are several possible explanations for these findings.
First, recurrence of anginal symptoms does not necessarily
lead to repeat revascularization after initially successful PCI.
Thus, it is possible that some of the HRQOL benefits
associated with stenting in our study reflect cases of symp-
tomatic restenosis that were felt (by either the patient or the
treating physician) to be sufficiently mild as not to warrant
repeat revascularization. Similarly, it is possible that among
patients who required repeat revascularization, the extent of
recurrent symptoms was less severe in the stent group.
Finally, it is possible that some of the HRQOL benefits
associated with stenting were due to a placebo effect in this
nonblinded trial as suggested by better mental health and
less bodily pain reported by stent patients at one month.
However, a placebo effect seems unlikely to account for
much of the six-month benefits we observed for the anginal
frequency and disease perception domains, given the limited
benefits of stenting on these subscales at the one-month
time point.
Study limitations. This study has several important limi-
tations. Baseline HRQOL data were not collected because
of concerns that their assessment would not be valid in the
immediate post-MI setting. Thus, we cannot exclude the
possibility that despite randomization there were differences
in baseline HRQOL that accounted for some of our
findings. The fact that baseline characteristics were quite
well-matched in our population and that our findings were
unchanged in multivariable analyses that adjusted for minor
imbalances in baseline characteristics tends to mitigate
against such selection bias, however.
From an analytic standpoint, the use of multiple statisti-
cal tests increases the risk of false positive findings. To
mitigate this effect, we reported p values adjusted for
multiple HRQOL comparisons in our primary analyses.
Moreover, the consistency of our findings across multiple
HRQOL domains argues against type I error as an impor-
tant explanation for our results. Missing data pose an
additional challenge for studies of HRQOL, where they
may occur nonrandomly. Not surprisingly, in our study
HRQOL scores tended to be higher for those patients who
responded at each of the three time points compared with
patients who missed one or more evaluations. Nonetheless,
missing data were relatively infrequent in our study, and our
findings were unchanged when we restricted our analysis to
complete responders (n  342), as well as with various data
imputation scenarios.
Finally, it is important to recognize that our findings
apply only to patients undergoing primary angioplasty for
AMI. It is possible that some of the benefits associated with
stenting in this study reflect specific differences in post-MI
recovery that may not be attained in the setting of elective
PCI. On the other hand, the HRQOL benefits associated
with reduced restenosis are similar to those previously
reported in the elective setting (14) and may, in fact, have
been blunted in certain patients since the target lesion
supplied infarcted myocardium.
Conclusions. In patients undergoing primary angioplasty
for AMI, initial stent placement is associated with signifi-
cantly better HRQOL at six-month follow-up but no
differences at one year. These findings were explained, in
part, by the lower incidence of clinically significant resten-
osis in the stent group but were also independent of the
restenosis benefits of stenting. In the absence of proven
1620 Rinfret et al. JACC Vol. 38, No. 6, 2001
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mortality benefits, these findings provide the major rationale
for stenting in the AMI setting. Further studies are needed
to determine whether the benefits of stenting on HRQOL
extend to patients undergoing nonemergent PCI as well.
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